A promising candidate from a novel class of antimicrobials acts by targeting an enzyme needed for making bacterial cell membranes and effectively inhibits drug-resistant pathogens including methicillin-resistant Staphylococcus aureus, according to scientists at Merck & Co. in Rahway, N.J. The new antimicrobial, called platensimycin and made by Streptomyces platensis, was identified from a soil sample that was collected in South Africa and subjected to an innovative screening procedure.
Platensimycin kills bacteria by binding and blocking ␤-ketoacyl-(acylcarrier-protein) synthase I/II (FabF), a key enzyme for synthesizing fatty acids that make up cellular membranes. A team led by biologist Jun Wang, structural biologist Stephen Soisson, and natural products chemist Sheo Singh found the compound while screening 250,000 natural product extracts gathered worldwide. Platensimycin consists of a pentacyclic ring connected by an amide bond to aminobenzoic acid, a chemical entity that Singh calls "the founding member of a new class of antibiotics." Just as medicinal chemists expressed great excitement about ␤-lactam-containing penicillin antibiotics in the 1940s, "this is equally exciting to medicinal chemists in 2006," he adds.
Potentially interesting ingredients in natural product extracts may occur in minute concentrations, Soisson points out. The Merck scientists designed a screening assay to detect antimicrobials that specifically inhibit FabF, a bacterial target that no other antibiotics recognize. The screening method depends on a strain of S. aureus that is engineered to make an antisense RNA that interferes specifically with the expression of FabF and whose own expression levels are controlled by an inducible promoter. Thus, increasing antisense expression reduces the amount of FabF synthesized, accentuating the sensitivity of cells to anything that inhibits FabF and, in turn, blocks essential cell membrane synthesis.
"We combined [this] target-based assay with whole-cell screening to find things missed in the past," Wang says. In those cell-based assays, platensimycin efficiently kills gram-positive bacteria, including methicillin-resistant S. aureus and vancomycin-resistant enterococci. The new antimicrobial also can inhibit gram-negative bacteria, but only when the efflux mechanism that pumps antibiotics out of such cells is disabled, including the effluxnegative strain of Escherichia coli that Merck researchers engineered for screening purposes. The behavior of that E. coli strain suggests that platensimycin could be effective more generally against gram-negative infections if it could be used with another drug that could block efflux, he points out.
The specific details of how platensimycin kills cells are still unknown, but the team knows that it is not "-cidal," but rather bacteriostatic and in this way similar to antibiotics such as chloramphenicol and tetracycline. At the molecular level, platensimycin interacts specifically with the acyl-enzyme intermediate of FabF, its target enzyme. X-ray crystallography suggests that a specific conformational change that occurs on acylation takes Three-dimensional image showing the new antimicrobial platensimycin interacting with the acylenzyme intermediate of FabF, its target enzyme, which is involved in fatty acid synthesis. (Image courtesy of Merck & Co., Inc.) place before the inhibitor binds the enzyme. Although drugs that target single enzymes are prone to resistance, "combining inhibitors of different steps in the fatty acid biosynthesis pathway may prove synergistic and greatly slow the emergence of resistance," says Steven Projan, vice president of Biological Technologies at Wyeth Research in Pearl River, N.Y.
Platensimycin proves highly effective when tested in mice infected with S. aureus, according to the researchers at Merck. They call it the "most potent inhibitor reported for the FabF/B condensing enzymes," noting that it is the only inhibitor of these targets that shows broad-spectrum activity, in vivo efficacy, and no toxicity. Additional details appear in the May 18, 2006 issue of Nature.
Despite heralded advances in genomics, molecular biology, and synthetic medicinal chemistry, most antibiotics now being used clinically are based on drugs that were developed 50 years ago. Those drugs work by interfering with either DNA, protein, or cell wall synthesis. During the recent past, several major pharmaceutical companies abandoned screening programs of natural products, saying that they considered them no longer lucrative, and switched to exclusively synthetic chemical strategies for identifying new drug candidates. "We are one of the few big pharma companies still doing antibiotic research and using natural products in the discovery process," Soisson says. Singh adds, "We are mining natural compounds with a discovery assay no one else is using."
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Carol Potera is a freelance writer in Great Falls, Mont. Some components of these response regulator systems are highly specialized. For instance, the receiver components in bacterial chemotaxis response systems typically are proteins containing a "CheY-like" signal receiver domain. However, other bacterial response regulator proteins often combine the receiver domain with an output domain, typically a DNAbinding protein, which can activate DNA transcription. Meanwhile, some output proteins in these response regulator systems are enzymes with welldescribed catalytic functions, while the biochemical activities of still other components remain mysterious.
What appears to account for the existence of so many response regulators? Galperin invokes what he calls the "Lego principle," referring to toy building blocks of simple shapes and mostly regular dimensions that are designed to attach to one another in countless combinations. "Almost any DNA-binding domain or metabolic enzyme [can] . . . fuse with [a] signal receiver domain to make an environmentally sensitive response regulator," he says. "Almost any combination works, and those that confer an
FDA Approves Vaccine To Protect against Papillomavirus
Officials of The Food and Drug Administration (FDA) in June approved a vaccine, called Gardasil, to protect women between 9 and 26 years of age against human papillomavirus (HPV). HPV infections, which cause genital warts and are a risk factor for cervical cancer, are the most common sexually transmitted disease in the United States. The recombinant DNA-based vaccine, which is produced by Merck & Co., Inc., of Whitehouse Station, N.J., is for use in younger women because it is effective only when administered before recipients become sexually active. In June, a committee of the Centers for Disease Control and Prevention recommended administering the vaccine to girls aged 11-12. In a related development, the Bill & Melinda Gates Foundation announced a $27.8 million grant to support a pilot project to administer the Merck HPV vaccine and a similar vaccine from GlaxoSmithKline to protect against such infections and cervical cancer in India, Peru, Uganda, and Vietnam. There are other general findings. For instance, bacteria that inhabit frequently changing environments are more complex-"smarter," according to Galperin-than those that inhabit stable environments or that are pathogens, even when genome sizes are near equal.
The database of response regulators that Galperin and his collaborators at NIH drew upon for their analysis and continue to make available to other scientists is highly regarded. It "is an incredibly valuable and easy-to-use resource for anyone who wishes to peruse the response regulator content of a particular species or examine the distribution of output domains across species," notes Robert Bourret of the University of North Carolina, Chapel Hill.
Bourret also calls the database "a potential gold mine" containing plentiful "raw material" for other kinds of analysis. For example, he envisions investigators constructing phylogenetic trees as a way of investigating the "coevolution of receiver and output domains." That or other studies should provide insights into the "nuances of how apparently similar receiver domains can regulate the activity of so many obviously different types of output domains," he points out. "Prokaryotic genomes do not appear to have much excess coding capacity, which suggests that if a gene is present, it is likely functional."
The NIH study also uncovers noteworthy differences in signal transduction between archaea and eubacteria. For instance, response regulators are far more numerous in eubacteria than in archaea. Furthermore, output domains are very different between the two. "None of the archaeal output domains belonged to any of the six classes of DNA-binding domains that make up two-thirds of bacterial response regulator output domains," Bourret notes. "This is particularly surprising because transcriptional regulators in archaea are believed to be largely bacterial in character. Also absent from the archaea are RNA-binding and protein-binding categories that are found among many eubacteria, he adds. "Most (57%) archaeal response regulators contained only a receiver domain, without an output domain."
In a more general way, the NIH study "provides instruction on how to perform a bioinformatic analysis of a diverse family of proteins that share a highly homologous domain," notes Alan J. Wolfe of Loyola University in Chicago, Ill. More to the point, he adds: "It demonstrates the importance of doing so." Probiotic microorganisms are intended to improve health-typically, either by attacking or interfering with pathogens in the body or by interacting in beneficial ways with the host immune system. Although far from universal, effective probiotic approaches include treatments for several bowel conditions, including diarrhea, pouchitis, and irritable bowel syndrome.
David Holzman
A great deal of work lies ahead in validating other probiotic therapies and in gaining acceptance for them, according to steering committee member John Bienenstock of McMaster University in Hamilton, Ontario, Canada. "A very important cultural appreciation has to occur that not all bugs are bad, and some are actually good for you," he says. Even so, he adds, "It isn't appreciated how widely probiotics are used commercially."
Many probiotics are being dispensed to consumers without critical scientific scrutiny, says Richard Walker, director of the Division of Bacterial, Parasitic, and Allergenic Products at the U.S. Food and Drug Administration (FDA), and cochair of the colloquium. "It's going to be a different ballgame going forward," he says. "In particular we need better clinical trials because in the past these haven't been set up as well as they could have been." Acknowledging this problem, the AAM report recommends that health claims made on probiotic product labels be backed up with convincing experimental proof. Quality control testing is also needed to ensure probiotic products live up to their ingredients lists, according to the report, including testing to ensure that they contain the microorganisms they claim and to authenticate their potency and safety.
In this vein, the AAM report argues for closer regulatory supervision of probiotics. In the United States, commercial probiotic products available in supermarkets and health stores are manufactured according to food regulations, not the more stringent rules that are applied to drugs or biologics such as vaccines. "There is a real need for FDA oversight," Wells says.
Despite problems with dubious claims about the efficacy of probiotics along with deficiencies in oversight, the report notes that several thoroughly investigated probiotic formulations are being used in clinical settings and other formulations show promise. "I think that probiotics are going to move from . . . anecdotal therapies to validated approaches," Walker says.
The AAM report is available on the Web at http://www.asm.org/Academy /index.asp?bidϭ43351.
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Bdellovibrio Make Fast Food of Gram-Negative Bacteria
Midgety but free-swimming, fastmoving, and wide-ranging, the Bdellovibrio bacteria and their near relatives, the Micavibrio, are voracious consumers-obligate predators-of gram-negative bacteria. This predatory disposition, which some experts call an "ancient behavior," while fascinating on its own terms, also could prove practical if these underappreciated microbes yield unusual enzymes The Bdellovibrio are "fearsome predators" that swim "amazingly quickly-at 160 m per second"-and dash around at such speeds "even within their prey," says symposium participant Elizabeth Sockett of Nottingham University in Nottingham, United Kingdom. Although more than one Bdellovibrio may latch onto a particular gram-negative bacterium, typically only one of those Bdellovibrio will enter the periplasm of that target cell-modifying its peptidoglycan (cell wall), and then feasting, replicating, and eventually lysing the target cell.
Systems Approach Depicts how Halobacterium Responds to Metal Fluxes
Bdellovibrio bacteria were first isolated in the 1960s. Bdellovibrio and like organisms (BALO) are widely distributed in diverse habitats, including soils, waste waters, and the open sea-typically at low population densities, according to symposium participant Edouard Jurkevitch of the Hebrew University of Jerusalem in Rehovot, Israel. In one survey of global soils, these predators fell mainly into two groups, the Bdellovibrio and the Bacteriovorax, both of which are ␦-proteobacteria, he says.
Within these general groups, there is considerable diversity, and that diversity appears to be recapitulated from one environment to another. Moreover, the diversity also can extend vertically, meaning different kinds of BALO may be found in the rhizosphere compared to nearby, surrounding soils. The diversity among niche-resident BALO may reflect population dynamics among the local prey upon which they depend for sustenance, Jurkevitch points out.
The recently sequenced genome of a Bdellovibrio species contains 3.8 megabases of DNA, making it about the same size as that of a typical gramnegative species such as Escherichia coli, Sockett notes. The Bdellovibrio genome is especially rich in genes for hydrolytic enzymes and also carries multiple flagella-encoding genes.
The more recently recognized Micavibrio are similarly predatory toward gram-negative bacteria, according to Jurkevitch. However, their flagella differ from those of the Bdellovibrio, as do the details of their predatory behaviors. Thus, for example, the Micavibrio also attach to the outer membranes of their prey, but they do not penetrate those cells. Instead, they "suck out the contents while remaining outside," where they replicate by means of binary fission, he points out.
Bdellovibrio mutants that swim more slowly have "slightly lower" predatory efficiency compared to wild-type cells, according to Sockett. However, nonmotile mutants still can penetrate their prey, meaning they "don't bore into prey using flagellar motility," she says. Instead, the Bdellovibrio apparently "squeeze through small holes in the outer membranes of prey," apparently relying on type 4 pili to serve as "retractable engines." Indeed, she adds, inactivating those pili makes such mutants nonpredatory.
Bdellovibrio provide a potential novel means for controlling biofilms and thus possibly some pathogens, according to Daniel Kadouri, who works with George O'Toole at Dartmouth Medical School in Hanover, N.H. For example, once it is administered to established Escherichia colior Pseudomonas fluorescens-containing biofilms, Bdellovibrio bacteriovorus 109J reduces them by about 10 3 to 10 4 , Kadouri says. "The Bdellovibrio attach and penetrate the biofilms, and reduce them extensively. You don't need a large amount or long exposure times." However, he notes, the Bdellovibrio appear to be more effective against planktonic cells of E.
Scanning electron micrograph of Bdellovibrio bacteriovorus (pink) preying on an E. coli biofilm. Image was taken after E. coli biofilm was developed for 18 hours on PVC plastic cover slip and exposed for 30 min to the predator B. bacteriovorus. Magnification, x20,000. (Image provided by Daniel Kadouri, Dartmouth Medical School, Hanover, N.H.) coli than against those in biofilms. "We don't know the basis of this apparent resistance."
In another series of in vitro experiments, Kadouri tested Micavibrio aeruginosavorus ARL-13, which has a narrower host range than Bdellovibrio and is an "exoparasite," against various strains of Pseudomonas aeruginosa, including clinical isolates. In general, treating with small amounts of Micavibrio reduced both biofilms and planktonic cells of P. aeruginosa by about 10 to 10 2 , although some strains tested proved resistant. "I think they [Bdellovibrio and Micavibrio] have therapeutic potential," he says.
Bdellovibrio might also be useful clinically for reducing levels of this or other gram-negative pathogens in body fluids or on the skin, according to Sockett. Although host immune responses might undermine this approach by knocking out the Bdellovibrio, provisional studies suggest that human immune responses to Bdellovibrio are less robust than are those to ordinary E. coli, she says. Another potential obstacle is that Bdellovibrio cells can be "decoyed" by gram-positive (nonsusceptible) bacteria in mixtures, which could mean that they would be inefficient at clearing gramnegative pathogens in mixed infections.
In terms of early evolution, one intriguing possibility is that Bdellovibrio, or their predecessors, were the source of modern mitochondria, Jurkevitch suggests. Unlike mitochondriacontaining eukaryotic cells, modern microbes are not equipped for endocytosis, and thus offer little in the way of explanation for how their forebears might have absorbed a microbial predecessor to the mitochondrion. Meanwhile, however, modern Bdellovibrio are adept at entering other microbial cells; the problem is that they cause havoc there. But, perhaps a toneddown, or facultative, Bdellovibrio penetrated another microbe eons ago, refrained from causing havoc, and became instead the endosymbiont of a then-new, eukaryotic kind of cell.
Jeffrey L. Fox Jeffrey L. Fox is the Microbe Current
Topics and Features Editor.
Eukaryotes Apparently Appeared Far Earlier, about When Archaea Arose
Eukaryotes apparently arose before, not after, cyanobacteria began supplying oxygen to the atmosphere 2.3 billion years ago, and they persisted despite the subsequent 100-million-year cold spell that iced the planet from the poles to the equator, according to Roger Buick of the University of Washington, Seattle, and his collaborators, whose report appears in the June issue of Geology. These findings open a new window on early life and carry big implications, according to evolutionary biologists. The new evidence pointing to this very early initial appearance of eukaryotes consists of sterol derivatives that were preserved in oil droplets-"inclusions"-encased in quartz crystals some 2.4 billion years ago. After using petrography and thermometrics to date the samples, the researchers found that they contain sterols, including cholesterol, which are produced almost exclusively by eukaryotes. The sterols that the researchers identified "are typical of a diverse eukaryotic biota," Buick says.
"These biomarkers suggest that oxygen was being produced long before the atmosphere became oxygenated, and that [eukaryotes] survived a 'Snowball Earth' glaciation," says Buick's collaborator Adriana Dutkiewicz of the University of Sydney, Australia. Because eukaryotes are not extremophiles, this evidence of extraordinarily ancient eukaryotes suggests that Snowball Earth "can't have been as environmentally extreme as some of the more hard-core models would have it," Buick adds.
The oil inclusions endured partly because they can withstand extreme conditions, including 250 -350°C, when sealed within quartz crystals, Dutkiewicz says. Once formed, such crystals exclude newer contaminants, thus maintaining a pristine molecular record.
The strongest geologic evidence previously available took eukaryotes back only 1.7 billion years, says Buick. This new evidence indicates that they predated the Great Oxidation Event, thereby putting "eukaryotes back to the time we first start seeing evidence of archaea." However, Norman Pace of the University of Colorado, Boulder, points out that Some Sexual and Social Oddities in Interplay of Viruses and their Hosts WO-B viruses indirectly manipulate the reproductive capacity of the jewel wasp, Nasonia vitripennis, according to Seth Bordenstein of the Marine Biological Laboratory (MBL) in Woods Hole, Mass., and his collaborators. They do so by interfering with the ability of symbiotic Wolbachia bacteria to cause cytoplasmic incompatibility in those insects hosts-in effect, hijacking sperm of the insect hosts and genetically tricking them to bear more infected females, the only sex that transmits the symbiotic bacteria, according to the report from the MBL group that appeared in the May 18 issue of PLoS Pathogens. genetic trees already suggested that eukaryotes go back around 3.5 billion years.
The research also opens a new window on the nature of early life. Microfossils and stromatolites indicate that there were microbes and hint at their sizes and shapes, but have little to say about their trophic and taxonomic affinities, Buick says. But long-preserved sterols or, if found, other organic molecules can provide clues about metabolic activities and phylogeny from early eras. Additionally, the techniques used to analyze the quartz-preserved specimens provide "another tool for searching for life on other planets, particularly extinct life," he says. "Previously, the organic chemistry dogma was that complex hydrocarbon molecules degraded over time. The fact that they survive for many billions of years means that we could seek them on a planet like Mars."
Buick and others tried to find biomarkers in oil droplets ten years ago, but the techniques were not sufficiently developed, he says. Although he and others then reported finding biomarkers in oil from shales from 2.7 million years ago, "People have been muttering that the findings might be an artifact because the biomarkers weren't sealed beyond the reach of any surface organic matter," he says. "For the last six to seven years I have had sleepless nights worrying about [this possibility]."
The research is arduous, says Dutkiewicz. "Once we select a sample that contains abundant oil dropletscalled oil inclusions-we crush the sample, isolate the mineral grains containing the oil inclusions, and clean them repeatedly with acid and solvents to remove any outside contamination. When the mineral grains are clean, we crush them to release the oil from the inclusions and analyze the molecular composition of the oil."
The research quality is excellent, says David Mossman of Mount Allison University, New Brunswick, Canada, who was not involved in the research. "This paper highlights a fresh application of cutting-edge scientific know-how in molecular biology applied to emergent phenomena-the Great Oxidation Event." 
David Holzman
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